AVBPArrivent Biopharma, Inc.
The Read
Historically, AVBP’s stock has shown a median absolute move of about 11%.
The schedule
- Tue6Oct
ArriVent BioPharma (AVBP) Stock Price, News & Analysis
- Wed18Nov
The Q3 earnings release will test the company's ability to meet revenue and guidance expectations amid ongoing regulatory and clinical challenges. The results will also provide insight into the impact of the recent phase 3 trial failure and potential misconduct investigation.
- Tue9Feb
The Q4 earnings release will test the company's ability to maintain momentum post-Q3 results, with a focus on pipeline progress and cash flow generation.
- Mon10May
The Q1 earnings release will test the company's ability to deliver on its long-term growth strategy, with a focus on new product launches and revenue diversification.
- Tue11May
The investor relations event will provide insight into the company's strategic priorities and financial outlook, with a focus on long-term growth and shareholder value.
- Mon9Aug
The Q2 earnings release will test the company's ability to deliver on its long-term growth strategy, with a focus on new product launches and revenue diversification.
Past
- Tue22Sep
Actual outcome: Bear · $15.12 at outcome
AVBP experienced a sharp decline due to concerns over a potential credit downgrade, which would impact its financial flexibility and investor confidence. The move suggests heightened risk perception around its debt obligations and liquidity position, leading to a significant sell-off in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-06: -46.9% from 2026-10-05 (~6.4σ). Target date 2026-09-29 reached; move through 2026-10-06 observed.
AVBP experienced a sharp decline due to concerns over a potential credit downgrade, which would impact its financial flexibility and investor confidence. The move suggests heightened risk perception around its debt obligations and liquidity position, leading to a significant sell-off in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-06: -46.9% from 2026-10-05 (~6.4σ). Target date 2026-09-29 reached; move through 2026-10-06 observed.
- Wed12Aug
Actual outcome: Bear · $29.57 at outcome
ArriVent BioPharma reported earnings in line with expectations, but the stock fell below the bear floor. The lack of positive catalysts and weak forward guidance contributed to the downward pressure, leading to a bear classification.
Quarterly earnings report updating the market on Furmonertinib's regulatory progress and ARR-002 pipeline developments.
- Thu25Jun
Actual outcome: Bull · $34.37 at outcome
AVBP successfully secured alternative, non-dilutive financing to extend its cash runway, eliminating the immediate need for the highly anticipated secondary equity offering. By removing the threat of severe shareholder dilution, this development cleared a major overhang on the stock and prompted shares to rally toward the bull target.
Market anticipation of a dilutive equity raise to replenish cash runway.
- Thu5Mar
Actual outcome: Bull · $25.25 at outcome
ArriVent met EPS estimates and provided updates on its clinical progress, which satisfied investor concerns regarding the Furmonertinib regulatory timeline and cash runway. The stock exceeded the bull target as analysts highlighted a positive trend in earnings revisions and maintained a 'Moderate Buy' consensus, signaling confidence in the company's long-term upside despite the high burn rate.
Investor focus will be on the cash balance ($112.67M cash and high burn rate of ~$35M/Q) and clarity on the regulatory filing timeline for Furmonertinib. High burn rate raises the probability of near-term financing.
